CXCL14 and neoplasm: Furthermore, IHC findings suggest that CXCL14 downregulation in ER-, PR-, human epidermal growth HER2+, TNBC, and basal-like subtypes may lead to immune evasion, reduced tumor immunogenicity, and increased aggressiveness.